First Tracks Q2 net loss $33.4M, cash $168M; ANB033 Fast Track, Cohort 1 data Q4

First Tracks Biotherapeutics, Inc.

Q2 2026 net loss $33.4M ($0.95/share) vs $42.4M ($1.47) year-ago; R&D spend $25.6M.
FDA granted Fast Track designation for ANB033 in celiac disease; Cohort 1 (n=30) fully enrolled, data Q4 2026.
Cohort 2 expanded to up to 40 patients; top-line data expected Q1 2027; EoE Phase 1b data Q3 2027.
Cash and investments $168.0M as of June 30, 2026; runway into Q2 2028.
Planning Phase 2 trials in two additional indications in H1 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.